National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 8437 [2024-02436]

Download as PDF Federal Register / Vol. 89, No. 26 / Wednesday, February 7, 2024 / Notices Dated: February 1, 2024. Lauren A. Fleck, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–02434 Filed 2–6–24; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting khammond on DSKJM1Z7X2PROD with NOTICES Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the cooperative agreement applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required); NIAID Clinical Trial Planning Grants (R34 Clinical Trial Not Allowed); NIAID Clinical Trial Implementation Cooperative Agreement. Date: February 29, 2024. Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate cooperative agreement applications. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3E70A, Rockville, MD 20892 (Video Assisted Meeting). Contact Person: Soheyla Saadi, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3E70A, Rockville, MD 20852, (240) 669–5178, saadisoh@ niaid.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: February 1, 2024. Lauren A. Fleck, Program Analyst,Office of Federal Advisory Committee Policy. BILLING CODE 4140–01–P VerDate Sep<11>2014 16:17 Feb 06, 2024 Jkt 262001 National Institutes of Health Center for Scientific Review; Notice of Closed Meetings BILLING CODE 4140–01–P [FR Doc. 2024–02436 Filed 2–6–24; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Molecular, Cellular and Developmental Neuroscience Integrated Review Group; Neural Oxidative Metabolism and Death Study Section. Date: February 28–29, 2024. Time: 8:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Place: Crowne Plaza National Airport, 1480 Crystal Drive, Arlington, VA 22202. Contact Person: Christine Jean DiDonato, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1014J, Bethesda, MD 20892, (301) 435–1042, didonatocj@csr.nih.gov. Name of Committee: Biobehavioral and Behavioral Processes Integrated Review Group; Biobehavioral Regulation, Learning and Ethology Study Section. Date: February 28–29, 2024. Time: 9:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Hybrid Meeting). Contact Person: Sara Louise Hargrave, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institute of Health, 6701 Rockledge Drive, Room 3170, Bethesda, MD 20892, (301) 443–7193, hargravesl@mail.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: Research on Current Topics in Alzheimer’s Disease and its Related Dementias. Date: February 28–29, 2024. Time: 9:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Bernard Rajeev Srambical Wilfred, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 8437 Bethesda, MD 20892, (301) 480–6813, bernard.srambicalwilfred@nih.gov. Name of Committee: Cardiovascular and Respiratory Sciences Integrated Review Group; Integrative Myocardial Physiology/ Pathophysiology A Study Section. Date: February 28–29, 2024. Time: 9:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Abdelouahab Aitouche, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4222, MSC 7814, Bethesda, MD 20892, 301–435– 2365, aitouchea@csr.nih.gov. Name of Committee: Infectious Diseases and Immunology B, Integrated Review Group; Transplantation, Tolerance, and Tumor Immunology Study Section. Date: February 28–29, 2024. Time: 10:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Carmen Angeles UfretVincenty, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594–0912, carmen.ufret-vincenty@nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Neurotechnology and Eye Diseases. Date: February 28, 2024. Time: 11:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Barbara Susanne Mallon, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 480–8992. mallonb@ mail.nih.gov. Name of Committee: Biology of Development and Aging Integrated Review Group; Mechanisms of Cancer Therapeutics, C Study Section. Date: February 29–March 1, 2024. Time: 8:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Gloria Huei-Ting Su, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301–496–0465, gloria.su@nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships: Topics in Biophysics and Biochemistry. Date: February 29–March 1, 2024. Time: 8:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. E:\FR\FM\07FEN1.SGM 07FEN1

Agencies

[Federal Register Volume 89, Number 26 (Wednesday, February 7, 2024)]
[Notices]
[Page 8437]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-02436]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the cooperative agreement applications, the disclosure 
of which would constitute a clearly unwarranted invasion of personal 
privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; NIAID SBIR Phase II Clinical Trial 
Implementation Cooperative Agreement (U44 Clinical Trial Required); 
NIAID Clinical Trial Planning Grants (R34 Clinical Trial Not 
Allowed); NIAID Clinical Trial Implementation Cooperative Agreement.
    Date: February 29, 2024.
    Time: 10:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate cooperative agreement 
applications.
    Place: National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3E70A, 
Rockville, MD 20892 (Video Assisted Meeting).
    Contact Person: Soheyla Saadi, Ph.D., Scientific Review Officer, 
Scientific Review Program, Division of Extramural Activities, 
National Institute of Allergy and Infectious Diseases, National 
Institutes of Health, 5601 Fishers Lane, Room 3E70A, Rockville, MD 
20852, (240) 669-5178, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: February 1, 2024.
Lauren A. Fleck,
Program Analyst,Office of Federal Advisory Committee Policy.
[FR Doc. 2024-02436 Filed 2-6-24; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.